Effect of phospholipase A2 inhibitors on mouse T lymphocytes. II. Phospholipase A2 inhibitors induce T cell hybridomas and a T cell clone for the formation of glycosylation-inhibiting factor.
The mouse T cell hybridoma 12H5 cells constitutively form glycosylation-enhancing factor (GEF) and produce both IgE-potentiating factor and ovalbumin (OVA)-binding GEF upon antigenic stimulation with OVA-pulsed macrophages. Culture of the 12H5 cells either with nonspecific glycosylation inhibiting factor (GIF) or with a phospholipase A2 (PLA2) inhibitor, ONO-RS-082, stopped the formation of GEF and induced the same cells to form GIF. Induction of the GIF formation by a PLA2 inhibitor was observed even when the 12H5 cells had been treated with mitomycin C, indicating that the switching from the GEF formation to the GIF formation was not due to selective proliferation of a GIF-producing subclone. The OVA-binding GIF produced by the PLA2-inhibitor-treated, antigen-stimulated 12H5 cells binds to homologous antigen (ovalbumin), and shares both antigenic determinant recognized by the monoclonal antibody 14-30 and the lipomodulin-determinant with antigen-specific suppressor inducer factor (TsiF). The present experiments also showed that a typical helper T cell clone, D10, G4.1 cells, constitutively formed GEF and that preculture of the T cell clone with IL-2 and the PLA2 inhibitor switched the cells from the formation of GEF to the formation of GIF. Upon stimulation with antigen-pulsed macrophages, the inhibitor-treated D10.G4.1 cells formed GIF having affinity for conalbumin. The results indicated that the same T cells have the capacity to form either GIF or GEF under different conditions, and suggested that the GIF-producing suppressor T cells may be a phenotype of a subset of helper T cells. Switching of the same cells from the GEF formation to the GIF formation by the PLA2 inhibitor and the ability of the inhibitor to enhance GIF formation suggested that PLA2-inhibitory activity or GIF activity of TsiF is involved in the suppressor T cell cascade.
Ohno
H
H
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Iwata
M
M
Katamura
K
K
Ishizaka
K
K
D062365:Aminobenzoates / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D002723:Chlorobenzoates; D002934:Cinnamates / Q000494:pharmacology*; D002999:Clone Cells / Q000187:drug effects; D005786:Gene Expression Regulation / Q000187:drug effects; D006825:Hybridomas / Q000187:drug effects; D008222:Lymphokines / Q000096:biosynthesis*; D008264:Macrophages / Q000502:physiology; D051379:Mice; D008806:Mice, Inbred AKR; D016685:Mitomycin; D008937:Mitomycins / Q000494:pharmacology; D010047:Ovalbumin / Q000378:metabolism; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D029584:Prostatic Secretory Proteins; D013601:T-Lymphocytes / Q000187:drug effects*; D062367:ortho-Aminobenzoates
D062365:Aminobenzoates; D000911:Antibodies, Monoclonal; D002723:Chlorobenzoates; D002934:Cinnamates; D008222:Lymphokines; D008937:Mitomycins; D029584:Prostatic Secretory Proteins; C043076:beta-microseminoprotein; C013059:immunoglobulin-binding factors; D062367:ortho-Aminobenzoates; D016685:Mitomycin; D010047:Ovalbumin; C060048:2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid; D010741:Phospholipases A; D054467:Phospholipases A2